Moyan Li
2026
From Regulatory Approvals to Patents: Cross-Domain Linking for Cardiovascular Device Traceability
Qingqing Yang | Haijiang Liu | Moyan Li
Proceedings of the 64th Annual Meeting of the Association for Computational Linguistics (Volume 1: Long Papers)
Qingqing Yang | Haijiang Liu | Moyan Li
Proceedings of the 64th Annual Meeting of the Association for Computational Linguistics (Volume 1: Long Papers)
Linking FDA-approved medical devices to their underlying United States Patent and Trademark Office (USPTO) patents enables critical applications such as recall root-cause analysis, M&A-driven IP discovery, and technology trajectory mapping. However, this cross-domain entity linking task remains unexplored due to severe **semantic gaps**: FDA documents focus on clinical outcomes, while patents describe technical mechanisms, yielding minimal lexical overlap. We formalize medical device-patent linking as a challenging cross-domain entity linking problem characterized by label scarcity and domain shifts. Using cardiovascular devices as a high-impact, representative domain featuring diverse technologies, high recall rates, and abundant disclosures, we construct a benchmark with 434 devices, 698K patents, and 585 high-fidelity expert-verified pairs. To address these challenges, we propose Bridge-MedDevKG, a coarse-to-fine framework that integrates (1) **MedDevOnto**, a domain-specific ontology that anchors device concepts via three-tier UMLS normalization; (2) **Multi-signal candidate generation** fusing company affiliation, semantic similarity, and ontology-weighted entity overlap; and (3) **Heterogeneous reranking** with multi-signal scoring and XGBoost classification on hard negatives. Our approach achieves a conservative lower-bound recall of 91.6% on the gold standard with 50.9% noise reduction, substantially outperforming LLM baselines under comparable evaluation. The resulting MedDevKG provides 6.8M high-confidence links, laying a scalable foundation for regulatory-IP integration across medical specialties.